ArticlePulmonary circulation2026
Identifying a Cardio-Hepatic Phenotype by Integrating the Albumin-Bilirubin Score Into Risk Assessment in Pulmonary Arterial Hypertension.
Article in Pulmonary circulation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Risk stratification is essential in pulmonary arterial hypertension (PAH), yet the prognostic utility of the albumin-bilirubin (ALBI) score as a marker of hepatic dysfunction remains underexplored. In this single-center study, we evaluated the clinical, neurohumoral, echocardiographic and hemodynamic correlates and prognostic value of the ALBI score, and to assess whether this score offers an incremental benefit over the Registry to EValuate Early And Long-term pulmonary arterial hypertension disease management (REVEAL) 2.0 risk score in patients with PAH. This study evaluated the prognostic value of the ALBI score and its incremental benefit in a cohort of 380 PAH patients (mean age 47.6 ± 18.3 years, 74.3% female). Patients were stratified into low (<= -2.60) and high (> -2.60) ALBI groups. High ALBI scores were significantly associated with worse functional class, reduced exercise capacity, elevated Nt-proBNP, right ventricular systolic dysfunction, and vena cava plethora (all
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.